Company Timeline

The MDNA journey began in 2001 with a research collaboration between scientists from universities on opposite sides of the Atlantic. We’ve come a long way since then. You can see many of the landmarks that have brought us to today below.

2002
Genesis Genomics is founded
2004
Biomarker for Prostate Cancer discovered
2008
Proof of concept studies completed for 11 different cancers
2008
American Journal of Clinical Pathology publication – Mtgenome Deletion Aids in the Identification of False- and True-Negative Prostate Needle Core Biopsy Specimens
2010
Genesis Genomics rebrands as Mitomics
2010
Prostate Cancer and Prostatic Disease publication – Accurate Prediction of Repeat Biopsy Outcomes by a mtDNA Deletion Assay
2011
Prostate Core Mitomic™ Test launched
2014
Mitomics is restructured under MDNA Life Sciences
2015
MDNA commences clinical validation of Mitomic™ Prostate Test in collaboration with the University of Cambridge, UK
2016
Mitomic™ Prostate Core Test Clinical Utility Paper published in American Health and Drug Benefits
2016
Collaboration agreement with the University of Oxford for development of Endometriosis Test
2017
BL&H appointed as Distribution Partner for the Mitomic™ Prostate Test in South Korea
2010-17
59 patents issued in 11 different countries, with a further 100 patents pending
2017
A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA "grey zone". published in the World Journal of Urology
2018
MDNA enters into exclusive licensing agreement with LabCorp®(LH) in the US.
2018
MDNA completes development of an RUO and a CE-IVD Real-Time PCR Kit for the Mitomic™ Prostate Test.